相关实验视频

Updated: Jun 14, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

在B细胞淋巴瘤中调整对Polatuzumab Vedotin的反应

Etienne Leveille¹, Shalin Kothari¹, Kadriye N Cosgun¹

¹Center of Molecular and Cellular Oncology, Yale University, New Haven, Connecticut.

Cancer discovery

|September 4, 2024

概括

新的发现揭示了为什么一些扩散型大B细胞淋巴瘤患者对拉图祖马布维多丁无反应. 机制包括降低CD79B可访问性和降低CD79B表达,影响治疗的有效性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

波拉图祖马布维多丁为扩散型大B细胞淋巴瘤 (DLBCL) 提供了一种新的一线治疗方法.
了解耐药机制对于优化治疗结果至关重要.
影响患者对波拉图祖马布维多丁反应的因素尚未完全阐明.

研究的目的:

确定DLBCL中波拉图祖马布维多丁敏感性降低的关键生物机制.
阐明参与抗 CD79B 向治疗的分子参与者.

主要方法:

研究了N-链接糖化在CD79B表位素可访问性中的作用.
评估了KLHL6 E3结合酶活性对CD79B表面表达水平的影响.
利用分子和细胞测试来分析药物敏感性.

主要成果:

由N结合甘氨基化引起的CD79B表位的可访问性降低被确定为一种耐药性机制.
由于KLHL6 E3酶活性导致的CD79B表面表达的降低,也导致不敏感性.
这些因素共同损害了波拉图祖马布 (polatuzumab) 的疗效.

结论:

CD79B的N链接糖化和KLHL6介导的CD79B下调是波拉图祖马布维多丁反应的关键决定因素.
这些发现为DLBCL的抵抗机制和潜在的治疗策略提供了洞察力.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...